Jefferson Kimmel Cancer Center Network
Policy and Procedure Manual

Table of Contents

1.0  JKCCN Staff  2
2.0  Membership and Affiliate Network Investigators  3
3.0  New Coordinator Training/Orientation  4
   3.1 Campus Keys: A Thomas Jefferson University (TJU) Unique Identifier  4
   3.2 IRB Training in Human Subjects Protection  5
   3.3 Introduction to CTEP/CTSU  5
   3.4 Eastern Cooperative Oncology Group (ECOG)  6
   3.5 National Surgical Adjuvant Breast and Bowel Project (NSABP)  6
   3.6 Radiation Treatment Oncology Group (RTOG)  6
4.0  JKCCN Accrual  7
   4.1 Monthly Accrual Log  8
5.0  CTSU  9
   5.1 CTSU Membership  9
   5.2 Enrolling Patients to CTSU Protocols  10
   5.3 Submitting Data through the CTSU  10
   5.4 Education and Promotion  10
6.0  ECOG  11
7.0  RTOG  12
8.0  NSABP Treatment  13
9.0  JOG  14
10.0 STAR Trial (NSABP)  15
11.0 Quality Assurance Program  16
   11.1 Purpose  16
   11.2 Functions  17
12.0 Regulatory/IRB  17
   12.1 IRB Training in Human Subjects Protection  17
   12.2 Disclosure of Conflicts of Interest  18
   12.3 Adverse Event Reporting  19
   12.4 IRB Guidelines on AE Reporting  20
13.0 IDS Pharmacy  24
14.0 Clinical Trial Payment  28
   14.1 Payment for Cooperative Group patient accruals  28
   14.2 Payment for RTOG patient accruals  28
   14.3 Payment for JOG patient accruals  28

Appendix I:  JKCCN Source Documents and Forms  29-48

Date last modified: October 5, 2009
Section 1.0
JKCCN Staff

Patricia Dugan
Administrative Director
215-955-1562
Patricia.Dugan@jeffersonhospital.org

Vicki Squire
Senior Outreach Coordinator
215-503-5641
Vicki.Squire@jeffersonhospital.org

Joshua Schoppe
Outreach Coordinator
215-955-0448
Joshua.Schoppe@jeffersonhospital.org

Sarah Charles
Genetic Counselor
215-955-1011
Sarah.Charles@jeffersonhospital.org

Rolma Mancinow
Clinical Research Coordinator
215-955-7954
Rolma.Mancinow@jeffersonhospital.org

Kelly Shipman
Clinical Research Coordinator
215-955-2135
Kelly.Shipman@jeffersonhospital.org

Rita Carlino
Program Coordinator
215-955-2412
Rita.Carlino@jeffersonhospital.org
### Jefferson Kimmel Cancer Center Network

#### Section 2.0
**Membership and Affiliate Network Investigators**

<table>
<thead>
<tr>
<th>Hem &amp; Onc Assoc. of NE PA (cont’d)</th>
<th>Nazareth Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristin M. Liptock, DO</td>
<td>Avnish Bhatia, MD</td>
</tr>
<tr>
<td>Gloria Morris, MD</td>
<td>Andrew Chapman, DO</td>
</tr>
<tr>
<td>Salvatore Scialla, MD</td>
<td>Michael Ramirez, MD</td>
</tr>
<tr>
<td>Abdalla Sholi, MD</td>
<td>Lewis Rose, MD*</td>
</tr>
<tr>
<td>Lisa Thomas, MD</td>
<td>John Smyles, MD</td>
</tr>
<tr>
<td></td>
<td>Alison Zibelli, MD</td>
</tr>
<tr>
<td><strong>Hudson Valley Oncology Associates</strong></td>
<td>Northeast Radiation Oncology Center</td>
</tr>
<tr>
<td>Michael Gallagher, MD*</td>
<td>Madhava Baikadi, MD</td>
</tr>
<tr>
<td></td>
<td>Harmar Brereton, MD*</td>
</tr>
<tr>
<td></td>
<td>Michael Gallagher, MD</td>
</tr>
<tr>
<td></td>
<td>Christopher Peters, MD</td>
</tr>
<tr>
<td></td>
<td>Chi Tsang, MD</td>
</tr>
<tr>
<td><strong>Jennersville Regional Hospital</strong></td>
<td>Pocono Medical Center</td>
</tr>
<tr>
<td>Martha Hosford, MD*</td>
<td>Michael Greenberg, MD*</td>
</tr>
<tr>
<td></td>
<td>William Ryan, MD</td>
</tr>
<tr>
<td></td>
<td>Kaoutar Tlemcani, MD</td>
</tr>
<tr>
<td><strong>Mercy Fitzgerald Hospital</strong></td>
<td>Riddle Memorial Hospital</td>
</tr>
<tr>
<td>Peter Ennis, MD</td>
<td>Lee Bogart, MD</td>
</tr>
<tr>
<td>Michael Mikhail, MD*</td>
<td>Christina Clay, MD</td>
</tr>
<tr>
<td>C. Jules Rominger, MD</td>
<td>Jessie DiNome, MD</td>
</tr>
<tr>
<td>Rene Rubin, MD</td>
<td>Melvyn Lapes, MD</td>
</tr>
<tr>
<td>Joseph Turchi, MD</td>
<td>Rashmi Sanjay, MD</td>
</tr>
<tr>
<td></td>
<td>Andrew J. Solan, MD*</td>
</tr>
<tr>
<td></td>
<td>Merrill Solan, MD</td>
</tr>
<tr>
<td><strong>Mercy Suburban Hospital</strong></td>
<td>Sacred Heart Hospital</td>
</tr>
<tr>
<td>William A. Biermann, MD</td>
<td>Neil Belman, MD</td>
</tr>
<tr>
<td>Lori Chapleskie Alfonse, MD</td>
<td>Mark Gittleman, MD</td>
</tr>
<tr>
<td>Rodwege DesNoyers, MD</td>
<td>Nalini Mehta, MD*</td>
</tr>
<tr>
<td>Joseph Tropea, DO*</td>
<td></td>
</tr>
<tr>
<td>Leslie Tupchong, MD, PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Methodist Hospital</strong></td>
<td>Sparta Cancer Treatment Center</td>
</tr>
<tr>
<td>Avnish Bhatia, MD</td>
<td>May Abdo-Matkivsny, DO</td>
</tr>
<tr>
<td>Andrew Chapman, DO</td>
<td>Michael Gallagher, MD*</td>
</tr>
<tr>
<td>Michael Ramirez, MD</td>
<td>Bodhan Halibey, MD</td>
</tr>
<tr>
<td>Lewis Rose, MD*</td>
<td></td>
</tr>
<tr>
<td>Jeffrey Rosenstock, MD</td>
<td></td>
</tr>
<tr>
<td>Alison Zibelli, MD</td>
<td></td>
</tr>
<tr>
<td><strong>Montgomery Hospital</strong></td>
<td></td>
</tr>
<tr>
<td>William A. Biermann, MD</td>
<td></td>
</tr>
<tr>
<td>Rodwege DesNoyers, MD</td>
<td></td>
</tr>
<tr>
<td>Estella Graeffe, MD*</td>
<td></td>
</tr>
<tr>
<td>Joseph Tropea, DO</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aria Health</th>
<th>Nazareth Hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dale Bryansmith, MD</td>
<td>Avnish Bhatia, MD</td>
</tr>
<tr>
<td>Frederick Dold, MD</td>
<td>Andrew Chapman, DO</td>
</tr>
<tr>
<td>Scot Fisher, DO</td>
<td>Michael Ramirez, MD</td>
</tr>
<tr>
<td>Eric Gressen, MD</td>
<td>Lewis Rose, MD*</td>
</tr>
<tr>
<td>Julia M. Kennedy, DO</td>
<td>John Smyles, MD</td>
</tr>
<tr>
<td>James Perry, MD</td>
<td>Alison Zibelli, MD</td>
</tr>
<tr>
<td>Shari B. Rudoler, MD</td>
<td></td>
</tr>
<tr>
<td>Allen E. Terzian, MD*</td>
<td></td>
</tr>
<tr>
<td><strong>Associates in Hematology-Oncology, PC</strong></td>
<td>Northeast Radiation Oncology Center</td>
</tr>
<tr>
<td>Arezoo Ghaneie, MD</td>
<td>Madhava Baikadi, MD</td>
</tr>
<tr>
<td>W. Alan Keogh, DO</td>
<td>Harmar Brereton, MD*</td>
</tr>
<tr>
<td>John Kosteva, MD</td>
<td>Michael Gallagher, MD</td>
</tr>
<tr>
<td>James D. Lebedda, MD, PhD</td>
<td>Christopher Peters, MD</td>
</tr>
<tr>
<td>Reza Mostofi, MD</td>
<td>Chi Tsang, MD</td>
</tr>
<tr>
<td>Nirmala Nathan, MD</td>
<td></td>
</tr>
<tr>
<td>Michael M. Soojian, MD</td>
<td></td>
</tr>
<tr>
<td>Erev Tubb, MD</td>
<td></td>
</tr>
<tr>
<td>Raymond Vivaqua, MD*</td>
<td></td>
</tr>
<tr>
<td><strong>Ephrata Community Hospital</strong></td>
<td>Pocono Medical Center</td>
</tr>
<tr>
<td>Cheryl Gardner, DO</td>
<td>Michael Greenberg, MD*</td>
</tr>
<tr>
<td>Renu Lamba, MD</td>
<td>William Ryan, MD</td>
</tr>
<tr>
<td>Michael Lambo, MD</td>
<td>Kaoutar Tlemcani, MD</td>
</tr>
<tr>
<td>Wilfred Layne, MD*</td>
<td></td>
</tr>
<tr>
<td><strong>Hem &amp; Onc Assoc. of NE PA</strong></td>
<td>Riddle Memorial Hospital</td>
</tr>
<tr>
<td>Christian Adonizio, MD</td>
<td>Lee Bogart, MD</td>
</tr>
<tr>
<td>Carl Barsigian, MD</td>
<td>Christina Clay, MD</td>
</tr>
<tr>
<td>Richard Emmanuelson, MD</td>
<td>Jessie DiNome, MD</td>
</tr>
<tr>
<td>William Heim, MD*</td>
<td>Melvyn Lapes, MD</td>
</tr>
<tr>
<td>W. Edward Jordan III, MD</td>
<td>Rashmi Sanjay, MD</td>
</tr>
<tr>
<td></td>
<td>Andrew J. Solan, MD*</td>
</tr>
<tr>
<td></td>
<td>Merrill Solan, MD</td>
</tr>
</tbody>
</table>

* Principal Investigator at institution
Section 3.0
New Coordinator Training Orientation

3.1 Campus Keys: A Thomas Jefferson University (TJU) Unique Identifier

JKCCN Contact: Vicki Squire, RN

A TJU campus key and password are required to access the following applications:

- Jefferson Remote Access Portal (RAP) [https://connect.tjuh.org](https://connect.tjuh.org)
- Within RAP, links to the Electronic adverse event reporting system (eSAEy) and the Electronic unanticipated problem reporting system (eazUP)

The following information is necessary to establish a campus key and should be submitted to Vicki Squire:

- Name
- Email address
- Work phone
- Home zip code
- Date of birth

It usually takes Jefferson’s Information Technology Department two weeks to process your campus key. They will call you to inform you of your campus key and initial password.

Please note: The remote access portal is the first point of entry to get to the eSAEy and eazUP applications; this is a two-step process. The remote access portal requires a password change every 3 months, but there is not an automatic notification process in place for alerting you to this requirement. If you are denied access, it will most likely be due to the need to change your password. To change your password go to the following link: [http://campuskey.tjuh.net/selfchangepwd.jsp](http://campuskey.tjuh.net/selfchangepwd.jsp)

The same password works for RAP, eSAEy, eazUP, and the JKCCN consent form repository.

Your campus key will always remain the same.
3.2 **IRB Training in Human Subjects Protection**

All personnel working on any aspect of clinical research must complete IRB training before participating in any aspect of clinical research, especially the consent process. Initially, two certifications must be completed: 1) Training in human subjects’ protection, and 2) HIPAA training.

For more information, please see the [Regulatory/IRB](#) section.

3.3 **Introduction to CTEP/CTSU**

**JKCCN Contacts:** Joshua Schoppe and Kelly Shipman

Thomas Jefferson University Hospital is a member of three federally-funded cooperative cancer research groups: Eastern Cooperative Oncology Group (ECOG), National Surgical Adjuvant Breast and Bowel Project (NSABP), and Radiation Therapy Oncology Group (RTOG). The three groups research new anti-cancer regimens to treat a variety of disease sites through the utilization of different modalities, including surgery, chemotherapy, and radiotherapy.

The division of the National Cancer Institute (NCI) that funds cooperative research groups is called the Clinical Trials Evaluation Program (CTEP). In order to take part in the cooperative research group program each clinical research associate, must obtain a CTEP Associate ID # by setting up a CTEP Identity and Access Management (IAM) account. Having this ID # will allow you to take full advantage of the tools and information these groups have to offer. This ID # will be necessary to set up log-in and password information for the website of the Clinical Trials Support Unit (CTSU), which provides expanded access to NCI-funded phase 3 clinical trials.

**Link to obtain CTEP ID #:** [https://eapps-ctep.nci.nih.gov/iam](https://eapps-ctep.nci.nih.gov/iam)

**New Accounts:**
- Click the Request New Account link at the bottom right.
- Follow the application instructions through four steps. A unique e-mail address is required.
- You will be asked to select three security questions, and one must be answered any time a temporary password is changed.
- When you receive your CTEP-IAM approval email, click the link provided in the email and activate your account by changing your temporary password to a permanent password.

Several resources are available on the CTSU website within the “Education and Resources” tab.

For additional information, contact the CTEP Registration Help Desk by phone at 301-496-9910 (Monday through Friday 8.30am to 4.30pm) or by e-mail at ctepreghelp@ctep.nci.nih.gov.

For more information, please see the [CTSU](#) section.
3.4 Eastern Cooperative Oncology Group (ECOG)

A multi-disciplinary organization devoted to the prevention, treatment, and cure of adult malignancies.

For more information, please see the ECOG section.

**JKCCN Contact:** Joshua Schoppe

3.5 National Surgical Adjuvant Breast and Bowel Project (NSABP)

A national cooperative group conducting clinical trials for treatment and prevention of breast and colorectal cancer.

For more information, please see the NSABP section.

**JKCCN Contact:** Vicki Squire

3.6 Radiation Treatment Oncology Group (RTOG)

A national cooperative group conducting clinical trials to evaluate new forms of radiotherapy delivery and to test new systemic therapies in conjunction with radiotherapy.

For more information, please see the RTOG section.

**JKCCN Contact:** Kelly Shipman
Section 4.0

JKCCN Accrual

Monthly Log

Contact: Rita Carlino

At the end of every month from Rita Carlino, Program Coordinator for the Jefferson Kimmel Cancer Center Network will send an e-mail that asks for your institution’s past month’s accrual. Please provide the following information:

- The number of patients accrued for each disease site
- The race and gender for each patient accrued

Note: Please also include patients enrolled to clinical trials that are not open through Jefferson.

Submission of the Monthly Log is expected to be sent in even if zero patients have been accrued during the past month.

Upon completion of the Log, please fax or e-mail your reply to Rita Carlino by the date indicated in her e-mail. No cover page is necessary.
### JEFFERSON CANCER NETWORK MONTHLY LOG

**TJU Accrual (All cooperative groups, JOG pharma, JOG/KCC/IIT's)**

<table>
<thead>
<tr>
<th>Study ID #</th>
<th>Disease Site</th>
<th>Patient Initials</th>
<th>Enrolling physician</th>
<th>Race</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Non-TJU Accrual – Other pharma (i.e. pharma not accessed through TJU)*

<table>
<thead>
<tr>
<th>Study ID #</th>
<th>Disease Site</th>
<th>Patient Initials</th>
<th>Enrolling physician</th>
<th>Race</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Refer to key above*
The CTSU is a service of the National Cancer Institute that provides for clinicians across the US and Canada access to cancer treatment trials.

Participation is open for members and affiliates of the following Cooperative Groups:

- ACOSOG
- CALGB
- NCCTG
- NCIC CTG
- ECOG
- GOG
- NSABP
- RTOG
- SWOG

**CTSU Administrator for the JKCCN:** Joshua Schoppe

**CTSU Data Administrator for the JKCCN:** Kelly Shipman

### 5.1 CTSU Membership

Membership Registration is facilitated by the Cancer Therapy Evaluation Program Identity and Access Management (CTEP-IAM) System. This is required for all investigators who treat patients and prescribe medications as well as all key clinical trial personal. The purpose of the CTEP-IAM is to provide a central validation of all staff involved in the conduct of CTEP-sponsored trials, to facilitate identification of personnel found on multiple Group rosters, to provide access to other CTSU and CTEP databases and programs and to track/support regulatory compliance for Group Administrators and CTSU regulatory staff. More information on CTSU membership, please use the following link: [https://www.ctsu.org/RegProced_ir-ar.asp](https://www.ctsu.org/RegProced_ir-ar.asp)

**Accessing Protocols and Documents:** Requires Password. You can search by cancer type, protocol ID number, and by lead cooperative group.

**Link to CTSU website:** [http://members.ctsu.org](http://members.ctsu.org)
5.2 **Enrolling Patients to CTSU Protocols**

- Required components prior to patient enrollment: Enrolling physician must be registered and credentialed with the CTSU, all required Site Registration materials must be received and approved by the CTSU, patient informed consent must be obtained, all protocol-specific pretreatment evaluations must be performed and eligibility criteria must be satisfied
- FAX the Patient Enrollment Transmittal Form and protocol-specific enrollment forms (Eligibility Checklist and Registration Form) to the CTSU at 1-888-691-8039. The CTSU Registrar Office is open Monday – Friday from 9am – 5:30pm.
- CTSU Patient Registrars will:
  - Confirm the regulatory requirements are met
  - Verify completeness of faxed enrollment forms
  - Contact sponsoring Group to register the patient
  - Obtain Patient Identification Number and randomization assignment
  - Convey patient ID# and randomization assignment to site
- For patient enrollments that must be completed within approximately 1 hour, please call the CTSU Cell Phone: 301-704-2376

5.3 **Submitting Data through the CTSU**

- Instructions are always specified in protocol
- For the majority of studies, data forms (CRFs) are to be submitted to the Group leading the trial, using the methods outlined in the CTSU Logistical Appendix of each protocol document.
- Some protocols require collection of special materials: tumor blocks, slides, and/or copies of X-ray films. Read the protocol and send materials as instructed
- Queries are usually generated by and sent to sites by the Lead Group. Query responses should be submitted back to the Lead Group in the manner specified in the query letter or protocol document

5.4 **Education and Promotion**

Information on CTSU procedures, protocol-specific materials, audit resources, and other helpful resources can be found by visiting the “Education and Resources” tab on the CTSU member website.

CTEP-IAM Fact Sheet: [https://members.ctsu.org/CTEP-IAM_FactSheet.pdf](https://members.ctsu.org/CTEP-IAM_FactSheet.pdf)
Section 6.0
Eastern Cooperative Oncology Group (ECOG)

Main Institution: Mayo Clinic (Rochester, MN)

Affiliate Institutions:
Albert Einstein Medical Center
Aria Health
Ephrata Community Hospital- Ephrata Cancer Center
Pocono Medical Center- Hughes Cancer Center
Hematology and Oncology Associates of NEPA, PC
Jennersville Regional Hospital
Thomas Jefferson University Hospital

Principal Investigator: William Tester, MD

Program Coordinator: Joshua Schoppe

Regulatory Contact: Rolma Mancinow

ECOG Coordinating Center
Address: Frontier Science, 900 Commonwealth Avenue, Boston, MA 02215
Phone: 617-632-3610
Fax: 617-632-2990

Link to ECOG website: http://www.ecog.org
Section 7.0
Radiation Therapy Oncology Group (RTOG)

Main Institution: Thomas Jefferson University Hospital, RTOG Institution # 601

Affiliate Institutions:
190   Pocono Cancer Center
0608  Hudson Valley Oncology Associates
0610  Sparta Cancer Center
2213  Northeast Radiation Oncology Center
5101  Albert Einstein Medical Center

Principal Investigator:  Maria Werner-Wasik, MD   215-955-7679

Contact:  Kelly Shipman

Regulatory Contact:  Rolma Mancinow

RTOG Headquarters
Address:  1818 Market Street, Suite 1600, Philadelphia, PA 19103
Phone: 215-574-3189 or 1-800-227-5463, x4189
Fax: 215-928-0153

Link to RTOG website:  http://www.rtog.org

For questions regarding data submission, please call the RTOG Data Management Main Telephone number at 215-574-3214.

Orientation:  A comprehensive orientation for Research Associates (RAs) is held every few months at RTOG headquarters in Philadelphia, as well as periodically at RTOG semi-annual meetings. An orientation schedule is listed on the RTOG website at http://rtog.org/members/RAcorner.html.

RTOG Audits:  Please e-mail Kelly Shipman to view a Powerpoint presentation pertaining to RTOG audits.
Jefferson Kimmel Cancer Center Network

Section 8.0
National Surgical Adjuvant Breast and Bowel Project
(NSABP Treatment Trials)

Main Institution: Kimmel Cancer Center at Jefferson, #717

Affiliate Institutions:
717-03 Mercy Fitzgerald Hospital
717-04 Aria Health
717-05 Riddle Memorial Hospital
717-07 Ephrata Community Hospital- Ephrata Cancer Center
717-08 Mercy Suburban Hospital-Norristown Regional Cancer Center
717-09 Associates in Hematology-Oncology, PC
717-10 Underwood Memorial Hospital
717-11 Sacred Heart Hospital
717-12 Pocono Medical Center- Hughes Cancer Center
717-13 Montgomery Hospital Medical Center
717-14 Hematology and Oncology Associates of NEPA, PC
717-15 Jennersville Regional Hospital
717-16 Sparta Cancer Center

Principal Investigator: Scott D. Goldstein, MD 215-955-5869

Program Coordinator: Vicki Squire, RN

Regulatory Contact: Rolma Mancinow

NSABP Biostatistical Center
Address: One Sterling Plaza, 210 North Craig St. Ste 500, Pittsburgh, PA 15213
Fax for case report forms: 412-622-2111

NSABP Clinical Coordinating Section
Phone: 800-477-7227
Email: ccs@nsabp.org
Nurses answer clinical questions related to protocol eligibility, treatment modifications, adverse events and other protocol logistics.

Link to NSABP Homepage: http://www.nsabp.pitt.edu

Date last modified: October 5, 2009
Section 9.0
Jefferson Oncology Group (JOG)

The Jefferson Oncology Group (JOG) is a cancer research consortium comprised of members of the Jefferson Kimmel Cancer Center Network and their affiliated physicians.

Group Chairperson: Rita Axelrod, MD 215-955-1965

JKCCN Contacts: Vicki Squire and Joshua Schoppe

- New JOG Trials are announced in the JKCCN E-News published bi-weekly. On the same day, site investigators receive an email announcing the new JOG trial.

- Most sponsors need to establish US sites early in their timeline leading to trial activation, so usually the announcement of a new JOG trial and polling for Network interest will be done in advance of study activation by 2 to 3 months.

- To ensure your site is selected, response to the announcement by the deadline stated in the E-newsletter is crucial.
Section 10.0
STAR Prevention Trial
(National Surgical Adjuvant Breast and Bowel Project)
Closed to Accrual November 4, 2004

Principal Investigator: Edith Mitchell, MD  215-955-8874

Program Coordinator: Vicki Squire, RN

Sites:
JEF 01- Kimmel Cancer Center at Jefferson
JEF 03- Riddle Memorial Hospital
JEF 05- Underwood Memorial Hospital
JEF 09- Mercy Fitzgerald Hospital
JEF 10- Aria Health
JEF 11- Ephrata Cancer Center
JEF 12- Sacred Heart Hospital

For questions concerning data submission call: 412-383-1100

Link to NSABP Homepage: www.nsabp.pitt.edu
Jefferson Kimmel Cancer Center Network

Section 11.0
Quality Assurance Program
(Cooperative Group Research)

11.1 Purpose

- To promote continuous audit readiness
- To mutually establish action plans for performance improvement, as needed

11.2 Functions

Consent Quality Review

- Consents are reviewed to ensure agreement with cooperative group’s template
- If discrepancies are noted, institutions are immediately notified and advice is given regarding informing patients

Patient Registration

- To ensure consent process is done in accordance with federal regulations and local IRB policy
- To enter patients into TJUH database by JKCCN, so that Network institutions can submit Serious Adverse Events for enrolled patients

Data Quality & Timeliness

- Quarterly and as needed, information on delinquent data is gathered by JKCCN and sent to institutions via e-mail
- Data Clarification Forms/queries from the cooperative groups are sent to Network sites for resolution

On-site Monitoring

- Periodic site visits to ensure research is conducted in accordance with federal, state, sponsor, and local IRB policies
- Review 20% of enrollment at each site and visit each site 2 times per year, or more often as needed
Section 12.0
Regulatory/IRB

12.1 IRB Training in Human Subjects Protection

Two IRB training certifications must be completed before any clinical research participation is initiated: 1) Training in Human Subjects Protection, and 2) HIPAA training.

Link to IRB training: http://www.jefferson.edu/ohr/irb_training/

Certifying Exam

- To be taken every 3 years
This module consists of a mini-course with a comprehensive test. Set aside 2-3 hours for this if you are new to clinical research.

Annual training

- To be taken every 2 years (in between the certifying exam)
This module takes less than one hour to complete.

HIPAA training

- To be taken once
This module takes less than one hour to complete.

Step-by-step instructions to complete IRB training: Select the box “New User”. This link will take you to a page where you can enter your campus key and password (if you do not have a campus key and password, please contact Vicki Squire). You will then be prompted to complete any training you are missing. If you are a new user, you must complete the certifying exam and the HIPAA exam to be compliant with the IRB regulations.

Please remember the system is CASE SENSITIVE.

It is important to print your training certifications and keep them on file.
12.2 Disclosure of Conflicts of Interest

A completed Disclosure of Conflicts of Interest form is required each fiscal year (July 1st to June 30th) by University Policy. Additionally, government regulations require that this type of certification is on file for all individuals who are listed as investigators and clinical research personnel on research projects and/or protocols at Thomas Jefferson University.

The TJU IRB will not accept any clinical trial application (addendums, annual reviews or amendments) from your institution until all personnel have completed and submitted the disclosure form.

An e-mail reminder to complete this form will be sent every year at the end of May.

The Disclosure of Conflicts of Interest form can either be completed online or by sending a printed copy to Rolma Mancinow at the JKCCN office.

Link to University Counsel Website:
http://www.jefferson.edu/universitycounsel/compliance_conflict.htm
### 12.3 Adverse Event Reporting

#### Serious Adverse Event versus Adverse Event

*(Specified in protocol)*

<table>
<thead>
<tr>
<th>Serious Adverse Events*</th>
<th>Adverse Events (Toxicities)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Expedited vs. Regular Reporting:</strong></td>
<td>Reporting to sponsor is usually due at the end of a cycle of treatment</td>
</tr>
<tr>
<td>- Specified in Protocol</td>
<td>Reporting requirements are usually outlined on protocol case report forms</td>
</tr>
<tr>
<td>- When in doubt as to regular vs. expedited: <strong>call sponsor or cooperative group</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Expedited reporting:**
- Reporting within 24 hours of notification of the event

**Regular reporting:**
- Time frame specified in protocol

**Actions to take within protocol parameters for reporting serious adverse events:**
- **JOG Trials**- complete sponsor SAE Form and call JKCCN Office
- **Cooperative Group Trials**- complete ADEERS and request copy of ADEERS sent to: [jkccn@kimmelcancercenter.org](mailto:jkccn@kimmelcancercenter.org)

**Thomas Jefferson University IRB Notification:**
- Submit an OHR-10
- Enter eSAEy system via Remote Access Portal [https://connect.tjuh.org](https://connect.tjuh.org)

*NOTE: All hospitalizations and deaths occurring during and within 30 days of protocol treatment are considered serious adverse events by the TJU IRB and require reporting via the eSAEy system.*

Please see the following pages for more detailed TJU IRB guidelines (taken from *Office of Human Research, Division of Human Subjects Protection Internal Policy*, Thomas Jefferson University and Hospitals, 2008).
Office of Human Research
Division of Human Subjects Protection Internal Policy

100 General Administration (GA)
Policy GA 120: Policy and Procedure for Reporting and Reviewing Unanticipated Problems Involving Risks to Subjects or Others

1. PURPOSE
The purpose of this policy is to ensure prompt reporting to the IRB of Serious Adverse Events (SAEs) and Unanticipated Problems (UAPs) by principal investigators. Regulatory requirements of both DHHS (45 CFR 46.103(b)(5)) and FDA (21 CFR 56.108(b)(1)) require that “each IRB shall follow written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the Department or Agency head of any unanticipated problems involving risks to subjects or others.”

An unanticipated problem is one that is not described in the protocol or consent form.

2. PROBLEMS TO BE REPORTED TO THE IRB
The following must be reported to the IRB:

- An Adverse Event (AE) is any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease, temporally associated with the use of a medical treatment or procedure that may or may not be considered to be related to the medical treatment or procedure.

- Serious Adverse Events (SAEs) are defined as any untoward occurrence that results in any of the following:
  - Death
  - A life-threatening adverse experience
  - Inpatient hospitalization or prolongation of an existing hospitalization
  - Persistent or significant disability or incapacity
  - Congenital anomaly or birth defect

- An Unanticipated Adverse Device Effect is any serious adverse effect on health or safety or any life-threatening problem or death caused by or associated with a device, if not identified in the device brochure, protocol, or consent form.

- Unanticipated Problems posing risks to subjects or others are unforeseen and indicate that participants or others are at increased risk of harm. Examples include but are not limited to the following:
  - An interim analysis of the data suggesting or indicating additional risk associated with a study procedure or test article.
  - A report (journal article or abstract, etc.) that shows that the risks or potential benefits of the research might now be different from those initially presented to the IRB.
  - A breach of confidentiality.
Office of Human Research  
Division of Human Subjects Protection Internal Policy

- Change in FDA labeling or withdrawal from marketing of a drug, device, or biological used in a research protocol.
- Change made to the research without prior IRB review to eliminate an apparent immediate hazard to a subject.
- Incarceration of a subject in a protocol not approved to enroll prisoners.
- An event that requires prompt reporting to the sponsor.
- Sponsor imposed suspension for risk.
- Complaint of a subject when the complaint indicates unexpected risks or cannot be resolved by the research team.
- A change to a protocol or procedure that is not pre-approved by the IRB.
- Protocol violation (an accidental or unintentional change to the IRB-approved protocol) that may harm subjects or others or that indicates that subjects or others may be at increased risk of harm.
- Other unanticipated information that indicates participants or others might be at increased risk of harm.

Some events do not qualify as AEs, SAEs or Unanticipated Problems posing risks to subjects or others. Most of these are events or circumstances encountered in the usual course of receiving medical attention. Examples of these are pain or minimal bleeding/bruising at the time of venipuncture, drowsiness after sedation, boredom while waiting for the scheduled visit or procedure, or other similar scenarios.

3. REVIEW OF SAEs AND UAPs

Electronically submitted on-site SAE reports are forwarded to two IRB reviewers, a pharmacist and a physician, who may either accept the report and forward it to the Adverse Events Coordinator in the DHSP, or request clarifications or changes prior to forwarding to the AE Coordinator. If the SAE requires amendment to the protocol or consent, an OHR-12 must be submitted for IRB review. Once accepted, the SAE information is incorporated into the Division of Human Subjects Protection AE Database and, if no protocol or consent form changes are required, a synopsis is presented to the convened IRB at the time of continuing review.

Reports of unanticipated problems will be reviewed by the Director or Associate Director, DHSP, to determine whether the problem meets the definition of an "unanticipated problem involving risks to subjects or others" before deciding what, if any, action should be taken.

If this pre-review indicates that the event reported does not meet the definition of an "unanticipated problem", then no further action is required and the report is filed in the DHSP.
Office of Human Research  
Division of Human Subjects Protection Internal Policy

If the unanticipated problem involves failure to follow federal or institutional human subjects regulations, further action may involve a non-compliance investigation/hearing.

If the pre-review determines that the problem reported represents an unanticipated problem involving risks to subjects or others, the Director/Associate Director, DHSP, will present the unanticipated problem to a convened IRB or assign a reviewer based on expertise and experience who will present the information to the Board. Immediate actions may also be necessary to eliminate any immediate hazards to subjects or others. If this is the case, the Director/Associate Director, DHSP, will notify the Board of the actions taken.

4. ACTIONS for CONSIDERATION BY THE CONVENED IRB
The convened IRB will consider the following actions during its deliberations:

- Modification of the protocol
- Modification of the information disclosed during the consent process
- Providing additional information to past subjects
- Notification of current subjects when such information might relate to their willingness to continue participation in the study
- Requirement that current subjects be re-consented
- Modification of the continuing review schedule
- Monitoring of the research and/or consent process by the DHSP QA/QI program
- Suspension of the research
- Termination of the research
- Referral to other organizational entities for further investigation

5. REPORTING OF ADVERSE EVENTS AND UNANTICIPATED PROBLEMS
On-site Adverse Events: On-site AEs and SAEs should be reported using the electronic AE reporting system (eSAE) accessed at http://www3.kimmelcancercenter.org/clinicaltrials/ae/ .

On-site SAEs that are deemed to be possibly or definitely related to the study article should be reported within 48 hours of knowledge of the event, except that death should be reported within 24 hours (one working day). Unrelated SAEs should be reported within 5 working days.

Off-site AEs/SAEs: Off-site AEs/SAEs or IND safety reports that require a change to the protocol and/or consent form should be submitted for review within 5 working days of knowledge of the event and be accompanied by a completed OHR10 off site report form and an OHR-12 form to effect the required amendment. Off-site AEs/SAEs or IND safety reports that do not require a change in the protocol or consent should not be reported to the IRB. A summary or itemized listing of these events should be included with the continuing review for the study.
Office of Human Research  
Division of Human Subjects Protection Internal Policy

AE Grading: AEs should be categorized for severity using the Common Toxicities Criteria (CTC) version 3.0. This is incorporated into the eSAEy reporting system. CTC version 3.0 can also be accessed at http://ctep.cancer.gov/.

Unanticipated Problems: Unanticipated problems that pose risk to subjects or others, and that are not AEs/SAEs should be reported within 10 working days using form OHR-20 along with an OHR-12 if an amendment is required.

Events that meet the reporting criteria in Policy GA 120 will be handled according to Policy GA 114, Reporting of Unanticipated Problems, Terminations, Suspensions and Non-compliance.

Approved by: (Signature on File)_____________ Date: __________
Vice President for Research

(Signature on File)_____________ Date: __________
Director, DHSP
Section 13.0
Investigational Agent Handling

Investigational Drug Service
Thomas Jefferson University Hospital
Department of Pharmacy

March 2009

Pharmacists: Linda Sailor, PharmD
Rania Sadaka, PharmD

Address: 111 South 11th Street
2290 Gibbon
Philadelphia, PA 19107

Telephone: 215-955-6923
Beeper: 877-656-5774
Fax: 215-955-7946

Service email: ids-service.pharmacy@jeffersonhospital.org
General Information

The TJUH Department of Pharmacy operates an Investigational Drug Service (IDS). The Service manages all investigational drug studies for TJUH inpatients. IDS provides the service for a fee to physicians who are conducting outpatient investigational drug studies.

IDS provides many services ranging from preparation and dispensing of investigational agents, completion of accountability records, procurement and appropriate storage of medication. IDS can also prepare randomization schedules for studies, provide blinding of medication and conduct services to health care professionals to ensure proper study management.

IDS is staffed by 2 full-time pharmacists from the hours of 7 am through 4:30 pm Monday through Friday. The service provides coverage 24 hours/day, 7 days/week. Off-hour coverage is provided through Night Call along with our pharmacy residents. Night Call pharmacists and residents have been fully trained in the area.

TO OBTAIN DRUG: For some studies, IDS is considered the depot pharmacy for the Jefferson Kimmel Cancer Center Network. Study drug will only be shipped to IDS, which will then transfer to Network sites.

IDS requires the following information prior to drug shipment to network site:

- Signed patient informed consent
- Physician order for study medication
- Confirmation of patient enrollment/registration into specific study
- Contact name, telephone number and address of Network Site

A fax coversheet is available to facilitate this process (please contact IDS to obtain a copy of this form). Please allow sufficient time to ship medication. Provide date needed at network site on fax coversheet.

NOTE: Cooperative group studies do not typically provide a start-up supply of medication. Drug will not be shipped until enrollment/registration is completed. Please keep this in mind when scheduling patients.

If you have any questions in regard to where drug must be obtained, you may either call the Jefferson Cancer Network or IDS for further assistance.

Drug Accountability Guidelines

POLICY: FDA regulations require investigators to establish a record of receipt, use and disposition of all investigational agents distributed by the Pharmaceutical Management Branch (PMB). The National Cancer Institute as a sponsor of investigational trials has the responsibility to assure the FDA that systems are in place by their investigators in their clinical trial program.

Investigators may practice and treat patients with investigational agents at more than one institution, however they must designate a single location as custodian to receive and manage the investigational agents. Simply stated there must be only one shipping address for a NCI designated physician. The Investigational Drug Service at TJUH is considered to be the central pharmacy for the Jefferson

Date last modified: October 5, 2009

25
Kimmel Cancer Center Network.

Procedures must be in place to maintain a satellite record for each agent transported to an affiliate institution. Transportation of NCI-supplied agents from a central location to a satellite must be done by institution staff or courier service. Secondary carriers such as Fed Ex or UPS must not be utilized. Please refer to the attached Transportation Policy and Procedure.

Industry-sponsored studies are not subject to the above regulations regarding transportation by staff and courier. Each industry-sponsored trial is handled on an individual basis, and study drug may be sent via FedEx for industry trials if Sponsor allows.

The entire procedure can be broken down into the following steps:

**NOTIFICATION OF PATIENT ENROLLMENT**
Once a patient has been identified at a satellite location, please complete the fax notification to IDS. Arrangements will be made to transport medication to the satellite location along with providing an estimated date of arrival.

**TRANSPORT OF DRUG TO SATELLITE**
Refer to the attached Transport Policy and Procedure. As stated in the policy, each shipment will be accompanied by a cover letter. Please inspect the shipment against the cover letter. If there are any discrepancies, please notify IDS immediately.

**RECEIPT OF DRUG AT SATELLITE**
Once drug has been inspected, complete a drug accountability record. IDS will provide an investigational drug accountability record with every shipment.

**STORAGE OF DRUG AT SATELLITE**
Investigational medication must be stored in a secure location where only authorized personnel have access. Store each investigational agent separately by protocol. Ensure proper temperature conditions are being maintained with valid documentation (ie; daily temperature logs).

**COMPLETION OF INVESTIGATIONAL DRUG ACCOUNTABILITY RECORDS**
The drug accountability record form (DARF) must be used for any transaction involving NCI-supplied agents from the PMB. This form may be downloaded from the CTEP web site.

The DARF can be broken down into 2 sections, upper portion and lower portion. The upper portion relates to specific information related to specific protocol and the treatment facility. The bottom portion is designed to record agent transactions (ie; receiving, dispensing). Please refer to the Pharmaceutical Management Branch Slideshow [http://ctep.info.nih.gov/branches/pmb/idh_slideshow.htm](http://ctep.info.nih.gov/branches/pmb/idh_slideshow.htm) for specifics on how to complete DARF slides 16 through 29.

Some helpful hints to keep in mind for completing DARFS:
- Use black pen only
- Do not use white-out. If an error is made, place a single line through the error, date and initial
- Complete DARF in its entirety
RETURN OF UNUSED INVESTIGATIONAL MEDICATION & COMPLETED ACCOUNTABILITY RECORDS

Once a patient has completed treatment at the satellite location or the study has been closed to enrollment, return any unused medication to IDS (central location). The DARF must be completed indicating that drug has been returned to IDS. The balance on the DARF from the satellite location must equal zero showing that there are no supplies at the satellite. IDS will maintain the original DARF with the satellite maintaining a copy of the DARF.
Section 14.0
Clinical Trial Payment

In order to receive appropriate payment for your enrolled patients, the JKCCN must receive notification when patients are enrolled at network affiliates. Notification is accomplished by faxing a completed JKCCN registration form to the JKCCN office at (215) 955-1020 at time of enrollment.

Payment for cooperative group (excluding RTOG) patient accruals

All cooperative group payments are sent to the JKCCN Office. JKCCN personnel process the checks and authorize payouts semi-annually. Each payment must first be tied to a patient accrual. To accomplish this:

- All registration forms must be received and databased
- Annual sub-award agreements must be signed by the network institutions and promptly returned to Jefferson’s Office of Research Administration

JKCCN prepares invoices detailing each accrual and the corresponding payment for that accrual. Checks and invoices are sent to network institutions in care of its research coordinator via Fed-Ex.

Please address questions to Rolma Mancinow (ECOG) and Kelly Shipman (NSABP).

Payment for RTOG patient accruals

Payments for RTOG patients are sent directly to Network institutions by the Group who is given credit for those patients.

Payment for JOG patient accruals

As monies are received from the sponsor, payments are made to network institutions according to the “per patient” amount and milestones stated in the contract.

Procedure: Karen Gosik of the Kimmel Cancer Center will email an invoice to the study coordinator at the Network institution. The invoice should be printed on the Network institution’s letterhead, signed by the Principal Investigator and sent to Karen Gosik.

Please address questions to Joshua Schoppe and Vicki Squire.
Appendix I:  
JKCCN Source Documents and Forms

- Study-specific source documents:
  - NSABP B-42 Patient’s Pill Diary
  - NSABP B-43 Screening Document
  - NSABP B-44-I (BETH) Screening Document

- Patient’s Pill Diary

- Oral Medication Record (for coordinator use)

- Concomitant Medications Log – Baseline

- Concomitant Medications Log – Update

- JKCCN Toxicity Flowsheet

- JKCCN QA Review Checklist

- JKCCN Registration Form

- My Usernames and Passwords

- Consent Review Source Document
NSABP B-42 Patient’s Medication Diary

Today’s date _____________ Agent _____________________ Dosage ___________
Patient Name ______________________ (or initials) Patient Study ID ____________

Adherence to treatment:

a) _____ # of pills dispensed on (date) ___

b) _____ # of pills returned on (date) ___

c) _____ # of pills expected to be taken

[(a) – (b)]/(c) x 100 = _____ % adherence to treatment

By patient report (every 6 months):

- What percentage of the patient’s study pills did she take?

○ All (100%)
○ Almost all (approximately 90%)
○ About three-fourths (approximately 75%)
○ About half (approximately 50%)
○ About one-fourth
○ Only a few (less than 25%)
○ None

- How was this percentage determined?

○ Patient estimate
○ Pill count
○ Both

Comments: _______________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________

Research Nurse/Coordinator’s Signature and Date:
_____________________________________ ___________
NSABP B-43 Eligibility Checklist – SCREENING

Patient Name: _______________________________ Date of Birth: __________

Conditions for Patient Eligibility

**A patient can not be considered eligible for this study unless all of the following conditions are met.**

1. _____ The patient is female.
2. _____ The patient is 18 years of age or older.
3. _____ The patient has a life expectancy of at least 10 years, excluding her diagnosis of breast cancer.
4. _____ The patient has an ECOG performance status of 0 or 1. **Performance Status:** ______
5. _____ The patient of reproductive potential is willing to be on non-hormonal birth control during the study and for 6 months after completion of trastuzumab.
6. _____ The patient has signed and dated IRB/EC-approved consent forms that conform to the guidelines of the local regulatory authority and of the institution. The consent forms include a consent form for pre-entry central HER2 testing and a consent form for participation in the BETH trial (see Section 14.1).
7. _____ The patient has consented to submit tumor samples from her breast surgery for HER2 testing.
8. _____ On histologic examination, the tumor must be ductal carcinoma in situ (DCIS). (Patients with mixed DCIS and lobular carcinoma in situ [LCIS] are eligible.)
9. _____ The patient’s DCIS must be HER2-positive as **determined by central testing** (see Sections 6.1 and 6.2 for details).
10. _____ The patient’s estrogen and/or progesterone receptor status must be determined prior to randomization. (Patients who have DCIS that is hormone receptor positive or negative are eligible.)
11. _____ All DCIS has been resected by lumpectomy.
12. _____ The margins of the patient’s resected specimen are histologically free of DCIS. For patients in whom pathologic examination demonstrates DCIS present at the line of resection, re-excision(s) may be performed to obtain clear margins. (Patients who require mastectomy are not eligible.)
13. _____ If axillary staging is performed, nodal staging is pN0, pN0(i-), pN0(i+) which is defined as isolated tumor cells ≤ 0.2nm, regardless of the method of detection, i.e., IHC or H&E, pN0(mol-), or pN0(mol+). **Note: Axillary staging is not required.** (Refer to AJCC Staging Criteria in the Treatment Trial Information section in the Members’ Area of the NSABP Web site for TNM nomenclature and staging information.) **Nodal staging:** ______
14. _____ The interval between the last surgery for excision of DCIS (lumpectomy or re-excision of lumpectomy margins) and randomization is no more than 120 days. **Date of surgery:** ______ **Randomization date:** ______

Conditions for patient ineligibility

**Any patient with one or more of the following conditions will be ineligible for this study.**

1. _____ Invasive (including microinvasion staged as T1mic) breast cancer. (Patients with DCIS “suspicious” for microinvasion, but not confirmed, are eligible.)
2. _____ Nodal staging of pN1 (including pN1mi). (Note: Axillary staging is not required.)
3. _____ DCIS is present in more than one quadrant (multicentric).
4. _____ Masses or clusters of calcification that are clinically or mammographically suspicious unless biopsied and proven to be benign. (If DCIS is found, the patient is eligible if the DCIS was in the same quadrant of the ipsilateral breast and was resected with clear margins.)

5. _____ Contralateral breast cancer (including DCIS).

6. _____ Whole breast irradiation administered before randomization. (Partial breast irradiation is prohibited.)

7. _____ Prior history of breast cancer, including DCIS. (Patients with a history of LCIS are eligible.)

8. _____ Prior anthracycline chemotherapy for any malignancy.

9. _____ Cardiac disease that would preclude the use of the drugs included in the B-43 treatment regimens. This includes but is not confined to:

   **Active cardiac disease**
   - Angina pectoris that requires the use of anti-anginal medication;
   - Ventricular arrhythmias except for benign premature ventricular contractions (PVCs) controlled by medication;
   - Conduction abnormality requiring a pacemaker;
   - Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and
   - Clinically significant valvular disease

   **History of cardiac disease:**
   - Myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LV function;
   - Documented congestive heart failure; or
   - Documented cardiomyopathy

10. _____ Uncontrolled hypertension, i.e., systolic BP greater than 180 mm/Hg and/or diastolic BP greater than 100 mm/Hg. (Patients with hypertension that is well controlled on medication are eligible.)

11. _____ Other nonmalignant systemic disease that would preclude a patient from receiving trastuzumab or radiation therapy or would prevent prolonged follow-up.

12. _____ Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization and is deemed by her physician to be at low risk of recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years; carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.

13. _____ Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing according to institutional standards should be performed for women of childbearing potential.)

14. _____ Administration of any investigational agent within 30 days before study entry.

15. _____ Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.

---

Form Completed By: ________________________________ Date: _____________

Investigator’s Signature: ____________________________ Date: ______________

Date last modified: October 5, 2009
NSABP B-44-I (BETH) Eligibility Checklist – SCREENING

Patient Name: ___________________________ Date of Birth: ____________

Conditions for Patient Eligibility:

A patient cannot be considered eligible for this study unless all of the following conditions are met.

1. ____ The patient is female.
2. ____ The patient is 18 years of age or older.
3. ____ The patient has a life expectancy of at least 10 years, excluding her diagnosis of breast cancer.
4. ____ The patient has an ECOG performance status of 0 or 1 (see Appendix D).
5. ____ The patient is willing to be on non-hormonal birth control during the study and for 6 months post-treatment.
6. ____ The patient has signed and dated IRB/EC-approved consent forms that conform to the guidelines of the local regulatory authority and of the institution. The consent forms include a consent form for pre-entry central HER2 testing and a consent form for participation in the BETH trial (see Section 14.1).
7. ____ The patient has consented to submit tumor samples from her breast surgery for HER2 testing.
8. ____ If the patient has had breast reconstruction, tissue expansion is not planned within 2 weeks before first dose of bevacizumab, during bevacizumab treatment, and until 6 weeks following the last dose of bevacizumab.
9. ____ The tumor is unilateral invasive adenocarcinoma of the breast on histologic examination.
10. ____ The breast cancer is HER2-positive based on the test results as follows:
    a. Local testing (if available) should demonstrate that the tumor is IHC 2+ or 3+ or is considered to be HER2-positive for gene amplification by FISH, CISH, or other in situ hybridization (ISH) method. (If local ISH test results are considered equivocal, the tumor can be submitted for central HER2 testing).
    b. Central testing (a requirement for ALL patients) must demonstrate that the tumor is HER2-positive, which is defined as FISH-positive and/or IHC 3+.
11. ____ All of the following staging criteria (according to the 6th edition of the AJCC Cancer Staging Manual) have been met:
    a. By pathologic evaluation, primary tumor must be pT1,3 Primary tumor:______
    b. By pathologic evaluation, ipsilateral nodes must be pN0, pN1, (pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b I ipsilateral nodes: ________
    c. If pN0, at least one of the following criteria must be met:
       i. Pathologic tumor size > 2.0 cm: Tumor size: ________
       ii. ER negative and PgR negative; ER neg: ____ PgR neg: ____
       iii. Histologic and/or nuclear grade 2 (intermediate) or 3 (high); or
       iv. Age < 35 years Age: ______
12. ____ The patient underwent either a ____ total mastectomy or ____ breast conserving surgery (lumpectomy).
13. ____ If the patient underwent lumpectomy, the margins of the resected specimen must be histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional operative procedures may be performed to obtain clear margins. If tumor is still present at the resection margin after re-excision(s), the patient must undergo total mastectomy to be eligible. (Patients with margins positive for lobular carcinoma in situ [LCIS] are eligible without additional resection.)
14. ____ If the patient underwent mastectomy, margins must be free of gross residual tumor. Patients with microscopic positive margins are eligible (see Section 8.8 for radiation therapy [RT] requirements).
15. ____ The patient completed one of the following procedures for evaluation of pathologic nodal status:

Date last modified: October 5, 2009
a. ____ Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes if the sentinel node (SN) is positive; 
b. ____ Sentinel lymphadenectomy alone if pathologic nodal staging based on sentinel lymphadenectomy is pN0, pN1mi or pN1b; or 
c. ____ Axillary lymphadenectomy without SN isolation procedure.

16. ____ The interval between the last surgery for breast cancer (treatment or staging) and randomization is at least 28 days but no more than 84 days. Date of surgery: _______ Randomization date: _______

17. ____ The patient must have ER analysis performed on the primary tumor prior to randomization. If ER analysis is negative, the PgR analysis must also be performed. Date of ER analysis: ________

18. ____ The most recent postoperative blood counts, performed within 6 weeks prior to randomization, met the following criteria: 
   a. ANC must be $\geq 1200/mm^3$ (1.2 x 10^9/L); ANC: ________
   b. Platelet count must be $\geq 100,000/mm^3$ (100.0 x 10^9/L); Platelets: ________
   c. Hemoglobin must be $\geq 10$g/dL. Hemoglobin: ________

19. ____ The following criteria for evidence of adequate hepatic function must be met based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: 
   a. Total bilirubin must be $\leq$ upper limit of normal (ULN) for the lab unless the patient has a bilirubin elevation $> ULN$ to 1.5 x ULN due to Gilbert’s disease or similar syndrome involving slow conjugation of bilirubin; and 
   Bilirubin: ________
   b. Alkaline phosphatase must be $\leq 2.5$ x ULN for the lab; and 
   Alkaline phosphatase: ________
   c. AST must be $\leq 1.5$ x ULN for the lab. AST: ________
   d. Alkaline phosphatase and AST may not both be $> ULN$. For example, if the alkaline phosphatase is $> ULN$ but $\leq 2.5$ x ULN, then the AST must be $\leq ULN$. If the AST is $> ULN$ but $\leq 1.5$ x ULN, then the alkaline phosphatase must be $\leq ULN$.

20. ____ If the patient’s AST or alkaline phosphatase is $> ULN$, she is eligible for inclusion in the study if liver imaging (CT, MRI, or PET scan performed within 3 months prior to randomization) does not demonstrate metastatic disease and the requirements in criterion # 18 are met.

21. ____ If the patient’s alkaline phosphatase is $> ULN$ but 2.5 x ULN, she is eligible for inclusion in the study if a bone scan or PET scan (performed within 3 months prior to randomization) does not demonstrate metastatic disease.

22. ____ The patient has met the following criteria for renal function, based on the results of the most recent postoperative tests performed within 6 weeks prior to randomization: 
   a. Serum creatinine is $\leq$ UNL for the lab. Serum creatinine: ________
   b. Measured or calculated creatinine clearance is $> 60$ mL/min (see Section 8.5.1 for instructions regarding calculation of creatinine clearance). Creatinine clearance: ________

23. ____ The patient’s urine dipstick indicates 0-1+ protein. If dipstick reading is $\geq 2+$, collect a 24-hour urine specimen, which must demonstrate $< 1.0$ g of protein per 24 hours. (Eligibility must be based on the most recent postoperative test(s) performed within 6 weeks prior to randomization.) Urine: ________

24. ____ LVEF assessment must be performed within 3 months prior to randomization. It is preferred that LVEF assessment be performed by 2-D echocardiogram; however, MUGA scan may be substituted based on institutional preferences. The LVEF must be $\geq 55\%$ regardless of the cardiac imaging facility’s lower limit of normal (LLN). (The same method should be used throughout the study; all assessments should be performed at the same cardiac imaging facility used at baseline.) 
LVEF: ______________

Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if trastuzumab and bevacizumab therapy can be administered, it is critical that this baseline study be an accurate assessment of the patient’s LVEF. If the baseline LVEF is $> 70\%$, the investigator is encouraged to have the accuracy of the initial LVEF result confirmed and to consider repeating the test if the accuracy is uncertain.
25. The ECG (performed within 3 months prior to randomization) has not demonstrated any of the following conditions:
   a. Ventricular arrhythmias except for benign premature ventricular contractions;
   b. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication; and
   c. Conduction abnormality requiring a pacemaker.

Conditions for Patient Ineligibility:

Patients with one or more of the following conditions are ineligible for this study.

1. Inflammatory breast cancer.
2. Definitive clinical or radiologic evidence of metastatic disease. (Chest imaging [mandatory for all patients] and other imaging [if required] must have been performed within 3 months prior to randomization.)
3. Synchronous contralateral breast cancer (invasive or noninvasive).
4. History of ipsilateral invasive breast cancer regardless of treatment or ipsilateral DCIS treated with excision and RT.
5. History of non-breast malignancies within the 5 years prior to study entry, except for the following: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinomas of the skin.
6. Previous therapy with anthracyclines, taxanes, carboplatin, trastuzumab, or bevacizumab for any malignancy.
7. RT, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to randomization.
8. Continued therapy with any hormonal agent such as raloxifene or tamoxifen (or other SERM) or an aromatase inhibitor. (Patients are eligible if these medications are discontinued prior to randomization.)
9. Any sex hormonal therapy, e.g., birth control pills, ovarian hormone replacement therapy, etc. as described in Section 8.10.4. Patients are eligible if these medications are discontinued prior to randomization.
10. Cardiac disease (history of and/or active disease) that would preclude the use of the drugs included in the treatment regimens. This includes but is not confined to:
   a. angina pectoris that requires the use of anti-anginal medication;
   b. ventricular arrhythmias except for benign premature ventricular contractions;
   c. supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication;
   d. conduction abnormality requiring a pacemaker;
   e. valvular disease with documented compromise in cardiac function; and
   f. symptomatic pericarditis.
11. Uncontrolled hypertension defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 90 mmHg, with or without anti-hypertensive medication. (BP must be assessed within 28 days prior to randomization.) Patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria. (See Appendix E for BP management requirements.)

Blood Pressure: ____________

12. History of hypertensive crisis or hypertensive encephalopathy.
13. History of TIA or CVA.
14. History of any arterial thrombotic event within 12 months before randomization.
15. Symptomatic peripheral vascular disease.
16. Intrinsic lung disease resulting in dyspnea.
17. _____ Unstable diabetes mellitus.
18. _____ Active infection or chronic infection requiring suppressive antibiotics.
19. _____ Any significant bleeding within 6 months before randomization, exclusive of menorrhagia in premenopausal women.
20. _____ Non-healing wound, skin ulcers, or incompletely healed bone fracture.
21. _____ Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure. See Sections 8.2 and 8.4 for instructions regarding initiation of therapy after device placement.)
22. _____ Anticipation of need for major surgical procedures during study therapy and for at least 3 months following completion of bevacizumab.
23. _____ Gastroduodenal ulcer(s) documented by endoscopy to be active within 6 months before randomization.
24. _____ History of GI perforation, abdominal fistulae, or intra-abdominal abscess.
25. _____ Known bleeding diathesis or coagulopathy.
26. _____ Requirement for therapeutic doses of coumadin or equivalent.
27. _____ Sensory/motor neuropathy ≥ grade 2, as defined by the NCI CTCAE v3.0.
28. _____ Conditions that would prohibit administration of corticosteroids.
29. _____ Chronic daily treatment with corticosteroids (dose of > 10 mg/day methylprednisolone equivalent) (excluding inhaled steroids).
30. _____ History of hypersensitivity reaction to drugs formulated with polysorbate 80.
31. _____ Pregnancy or lactation at the time of study entry. (Note: Pregnancy testing must be performed within 14 days prior to randomization according to institutional standards for women of child-bearing potential.)
32. _____ Other malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow-up.
33. _____ Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.
34. _____ Use of any investigational product within 4 weeks prior to enrollment in the study.
35. _____ Pregnancy at time of study entry.

Form Completed By: _____________________ Date: _____________
Investigator's Signature: ____________________________ Date: ______________
PATIENT'S MEDICATION DIARY

Today’s date ________________ Agent __________________ Dosage ___________
Patient Name ______________ (or initials) Patient Study ID ________________
Cycle #: ______ Dates of cycle: ________________ Protocol: _____________

INSTRUCTIONS TO THE PATIENT:
1. Complete one form for each __________ while you take ________________.
2. You will take your dose of __________________________ (protocol-specific instructions).
3. Record when you took the pills and any comments and/or side effects.
4. Please return this form to your study coordinator when you go for your next appointment.

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>AM</th>
<th>PM</th>
<th>Comments, Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Physician’s Office will complete this section:
Adherence to treatment:
a) _____ # of pills dispensed
b) _____ # of pills returned
c) _____ # of pills expected to be taken
\[(a) – (b)]/(c) x 100 = _____ % adherence to treatment

Research Nurse/Coordinator’s Signature and Date: ________________________ _________

Date last modified: October 5, 2009
Oral Medication Record  
(for coordinator use only)

Today’s date: ______________ Agent: _______________ Dosage: __________

Patient Name: ____________________ (or initials) Patient Study ID: __________

Protocol: ______________________

Adherence to treatment:

a) _____ # of pills dispensed on ___(date)___

b) _____# of pills returned on ___(date)___

c) _____# of pills expected to be taken

[(a) – (b)]/(c) x 100 = _____ % adherence to treatment

Comments: ______________________________________________________________

________________________________________________________________________

________________________________________________________________________

Research Nurse/Coordinator’s Signature and Date:

________________________________________________________________________

_________________________________ ___________
## Concomitant Medications and OTC Supplements – Baseline

Today’s date: __________ Patient Name: ___________________________ (or initials)
Patient Study ID: __________ Protocol: __________________

<table>
<thead>
<tr>
<th>Product Name and/or Generic Name and Dose</th>
<th>Indication</th>
<th>Start Date</th>
<th>End Date (or indicate if ongoing)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td><strong>/</strong>/____ □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td><strong>/</strong>/____ □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td><strong>/</strong>/____ □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td><strong>/</strong>/____ □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td><strong>/</strong>/____ □ ongoing</td>
</tr>
</tbody>
</table>

Form Completed By: ____________________________ Date: __________
Research Nurse/Coordinator’s Signature: __________________________ Date: _______
# Concomitant Medications and OTC Supplements – Update (Cycle # ____)

**Today’s date:** __________  **Patient Name:** ___________________________ *(or initials)*  
**Patient Study ID:** __________  **Protocol:** ___________________________

<table>
<thead>
<tr>
<th>Product Name and/or Generic Name and Dose</th>
<th>Indication</th>
<th>Start Date</th>
<th>End Date (or indicate if ongoing)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em>/____</td>
<td><em><strong>/</strong></em>/____  □ ongoing</td>
</tr>
</tbody>
</table>

**Form Completed By:** ______________________________ **Date:** __________

**Research Nurse/Coordinator’s Signature:** ___________________________ **Date:** _______

---

Date last modified: October 5, 2009
## Jefferson Kimmel Cancer Center Network Toxicity Flowsheet

<table>
<thead>
<tr>
<th>Date</th>
<th>Brief Description of Event</th>
<th>CTC Grade</th>
<th>Attribution (related to therapy)</th>
<th>Action (check all that apply)</th>
<th>Outcome</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>Unrelated</td>
<td>none required</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>Unlikely</td>
<td>dose reduced*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Possible</td>
<td>dose held*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>Probable</td>
<td>AdEERS</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>Definite</td>
<td>IRB notified</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>Unrelated</td>
<td>none required</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>Unlikely</td>
<td>dose reduced*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Possible</td>
<td>dose held*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>Probable</td>
<td>AdEERS</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>Definite</td>
<td>IRB notified</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>Unrelated</td>
<td>none required</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>Unlikely</td>
<td>dose reduced*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Possible</td>
<td>dose held*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>Probable</td>
<td>AdEERS</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>Definite</td>
<td>IRB notified</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>0</td>
<td>Unrelated</td>
<td>none required</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>Unlikely</td>
<td>dose reduced*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Possible</td>
<td>dose held*</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3</td>
<td>Probable</td>
<td>AdEERS</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>Definite</td>
<td>IRB notified</td>
<td>□ resolved □ ongoing</td>
<td></td>
</tr>
</tbody>
</table>

* Details of any type of dose adjustment must appear elsewhere in a source document

* In follow-up continue to capture event on this flowsheet until return to baseline

* CTC Version per protocol

### Common symptoms to review
- Allergic reaction
- Neutrophils (ANC)
- Hemoglobin
- Platelets
- Metabolic
- Fatigue
- Fever
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Mucositis
- Anorexia
- Rash/Desquamation
- Pain
- Peripheral Neuropathy
- Dyspnea
- Cough
- Alopecia
- Hot Flashes
- Ammenorrhea
## JKCCN Quality Assurance Review

### Consent Process

<table>
<thead>
<tr>
<th></th>
<th>Main Consent</th>
<th>Tissue Consent</th>
<th>Addendum Consent</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Valid consent used</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>TJU consent used?</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>b. Questions answered, if any</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>c. Signed and dated (all signature lines dated and complete)</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>d. Each page initialed and dated</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>e. Consent process documented in</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>Progress note?</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>Consent review source document?</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
<tr>
<td>f. Re-consent process executed?</td>
<td>Yes</td>
<td>No</td>
<td>N/A</td>
</tr>
</tbody>
</table>

1. Valid consent used
2. Questions answered, if any
3. Signed and dated (all signature lines dated and complete)
4. Each page initialed and dated

### Eligibility

a. Complete Checklist | Yes | No | Comments: 

  i. Cooperative group checklist used | Yes | No |
  ii. JKCCN checklist used | Yes | No |

b. Checklist signed and dated | Yes | No | Comments: 

c. Source Documents complete | Yes | No |
d. Source documents signed and dated | Yes | No |
e. Stratification factors documented | Yes | No |
If yes, note here: 

### Treatment

a. Verification of correct BSA and initial dosage
   - Height: __________ Weight: __________ BSA: __________ | Yes | No |
   - Correct drug sources | Yes | No |
   - Dose adjustment as per protocol | Yes | No | N/A |
If yes, explain: 

---
(Treatment cont’d)

d. For NSABP trials, all lab results reviewed and documented before chemo hung all cycles
   □ Yes □ No □ N/A
   If no, explain:


e. Use of AE flowsheet (JKCCN or site-specific) all cycles
   □ Yes □ No
   If no, explain:


f. Complete physician notes (PS, AE’s, SAE’s, dose adjustment) all cycles
   □ Yes □ No
   If no, explain:


g. Serious adverse events (SAE’s)?
   □ Yes □ No
   If yes, documented and reported per protocol to
   AdEERS?
   □ Yes □ No
   TJU IRB?
   □ Yes □ No
   Comments:


h. Oral Medication compliance documented
   □ Yes □ No
   Pill Count?
   □ Yes □ No
   Patient Diary?
   □ Yes □ No
   Comments:


i. Timely Data Submission (within 3 months)
   □ Yes □ No
   Comments:


4. Study medication logs and supplies
a. Use of current NCI logs (DARFs)
   □ Yes □ No

b. Complete
   □ Yes □ No
   Comments:


c. Accurate
   □ Yes □ No
   Comments:


d. Corrections initialed and dated
   □ Yes □ No

e. Returned/destroyed drug per protocol
   □ Yes □ No
   Comments:


Comments:


Date last modified: October 5, 2009
# Workspace/Notes

## Treatment Cycles

<table>
<thead>
<tr>
<th>Cycle #</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle #1</td>
<td>Dates 1</td>
</tr>
<tr>
<td>Cycle #2</td>
<td>Dates 2</td>
</tr>
<tr>
<td>Cycle #3</td>
<td>Dates 3</td>
</tr>
<tr>
<td>Cycle #4</td>
<td>Dates 4</td>
</tr>
<tr>
<td>Cycle #5</td>
<td>Dates 5</td>
</tr>
<tr>
<td>Cycle #6</td>
<td>Dates 6</td>
</tr>
<tr>
<td>Cycle #7</td>
<td>Dates 7</td>
</tr>
<tr>
<td>Cycle #8</td>
<td>Dates 8</td>
</tr>
<tr>
<td>Cycle #9</td>
<td>Dates 9</td>
</tr>
<tr>
<td>Cycle #10</td>
<td>Dates 10</td>
</tr>
</tbody>
</table>

## BSA Calculation

Parameter for dose change:

<table>
<thead>
<tr>
<th>Cycle #</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle #1</td>
<td>Dates 1</td>
</tr>
</tbody>
</table>

## Dose Delays:

<table>
<thead>
<tr>
<th>Cycle #</th>
<th>Dates</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle #1</td>
<td>Dates 1</td>
<td>Reason 1</td>
</tr>
<tr>
<td>Cycle #2</td>
<td>Dates 2</td>
<td>Reason 2</td>
</tr>
</tbody>
</table>

## Dose Modifications:

<table>
<thead>
<tr>
<th>Cycle #</th>
<th>Dates</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cycle #1</td>
<td>Dates 1</td>
<td>Reason 1</td>
</tr>
<tr>
<td>Cycle #2</td>
<td>Dates 2</td>
<td>Reason 2</td>
</tr>
</tbody>
</table>

## Items for follow-up and action plan

<table>
<thead>
<tr>
<th>Deviation</th>
<th>Action Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

JKCCN Coordinator Signature: _____________________________  Date: __________________

Site Coordinator Signature: _____________________________  Date: __________________

Date last modified: October 5, 2009
Please submit this form to the JCN in a timely fashion. * Indicates Required Field

**Clinical Trial Patient Registration Form**

<table>
<thead>
<tr>
<th>Unique Patient Identifiers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Institution:* __________________________</td>
</tr>
<tr>
<td>Med Rec #:* __________________________</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Last Name:* __________________________</td>
</tr>
<tr>
<td>MI: __________________________</td>
</tr>
<tr>
<td>First:* __________________________</td>
</tr>
<tr>
<td>Birth Date:* (ex: mm/dd/yyyy)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Race*</th>
<th>Ethnicity*</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHITE</td>
<td>Hispanic or Latino</td>
</tr>
<tr>
<td>Black or African American</td>
<td>Not Hispanic or Latino</td>
</tr>
<tr>
<td>Asian</td>
<td>Unknown</td>
</tr>
<tr>
<td>American Indian/Alaska Native</td>
<td></td>
</tr>
<tr>
<td>Native Hawaiian/Pacific Islander</td>
<td></td>
</tr>
<tr>
<td>More Than One Race</td>
<td>Male</td>
</tr>
<tr>
<td>Unknown</td>
<td>Female</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Trial Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial #:* (IRB #, Coop Group #, or JOG #)</td>
</tr>
<tr>
<td>Trial Arm:* __________________________</td>
</tr>
<tr>
<td>Cohort: __________________________ (if applicable)</td>
</tr>
<tr>
<td>Sequence #:* __________________________</td>
</tr>
<tr>
<td>Notes: (optional) __________________________</td>
</tr>
</tbody>
</table>

| Enrolling MD:* __________________________ |
| Other MD: __________________________ (multi-modality, surgical, etc) (optional) |
| Disease Site:* __________________________ |
| Date Enrolled:* (ex: mm/dd/yyyy) |

<table>
<thead>
<tr>
<th>Late Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>- if this form is being submitted more than one month past the &quot;Date Enrolled&quot; above, please include the patient status and any other applicable information</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient Status:*</th>
<th>Allre</th>
<th>Expired</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Off Drug: (ex: mm/dd/yyyy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Expired: (ex: mm/dd/yyyy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Off Study: (ex: mm/dd/yyyy)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Name of Submitter:* __________________________ |
| Phone #:* __________________________ |

Date last modified: October 5, 2009
MY USERNAMES & PASSWORDS

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________

Group: ____________________
Username: _________________
Password: _________________
Jefferson Kimmel Cancer Center Network

CONSENT REVIEW SOURCE DOCUMENT

Patient Name: ___________________________  Study #: ___________________________

Protocol: ___________________________  Consent Version date: ___________________________

Consent Expiration Date: ___________________________

The following were discussed with the patient:

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Purpose of the study/who are the participants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td>Study design (schedule of the trial)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td>Schedule of study tests</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.</td>
<td>Study specific questionnaires</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5.</td>
<td>Potential side effects</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.</td>
<td>All trial medications disclosed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td>Follow-up schedule after active treatment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8.</td>
<td>Confidentiality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9.</td>
<td>Pregnancy statement reviewed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.</td>
<td>Pregnancy while on the trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.</td>
<td>Voluntary participation /withdrawal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.</td>
<td>Alternative options to the clinical trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.</td>
<td>Potential benefits of a clinical trial</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.</td>
<td>The screening process</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.</td>
<td>The randomization process</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.</td>
<td>Potential re-consenting upon new findings</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.</td>
<td>Blinding / un-blinding</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18.</td>
<td>Clinical trials phone numbers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.</td>
<td>Contacts for patient after hours / weekends</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20.</td>
<td>Contact clinical trials if hospitalized / ER visit</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21.</td>
<td>No payment for being in the study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22.</td>
<td>Any compensation for illness/injury</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23.</td>
<td>Insurance/Payment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24.</td>
<td>All patient questions answered</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25.</td>
<td>Copy of consent given to patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26.</td>
<td>All sub-studies discussed with patient and related questions in consent form answered (i.e., PK, PG, blood &amp; tumor samples for research, etc.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27.</td>
<td>Consent form addendum signed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28.</td>
<td>Short form consent signed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29.</td>
<td>Translated consent signed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30.</td>
<td>Translator required:</td>
<td>Name of translator:</td>
<td>Language:</td>
</tr>
</tbody>
</table>

Remarks: ___________________________________________________________________________
_________________________________________________________________________________
_________________________________________________________________________________

Signature: ___________________________  Date: ___________________________

Date last modified: October 5, 2009
Jefferson Kimmel Cancer Center Network
CONSENT REVIEW SOURCE DOCUMENT
(Amendment/Additional information)

Patient Name __________________________ Study #: _______________________.
Protocol: __________________________ Amendment #: _______________________.
Consent Version date: _______________________.

The following were discussed with the patient:

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Changes to the consent</td>
<td></td>
</tr>
<tr>
<td>All questions answered</td>
<td></td>
</tr>
<tr>
<td>Copy of consent given to patient</td>
<td></td>
</tr>
<tr>
<td>Translated consent signed</td>
<td></td>
</tr>
<tr>
<td>Translator required</td>
<td></td>
</tr>
</tbody>
</table>

Name of Translator __________________________ Language: __________________________

Comments:

________________________________________ Date: __________________________

Signature: __________________________